JP
DOVA

John Paulson’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

John Paulson’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-550,681
Closed -$13.2M – 56
2017
Q4 		$13.2M Hold
550,681
– – 0.26% 43
2017
Q3 		$9.98M Sell
550,681
-70,951
-11% -$1.68M 0.18% 44
2017
Q2 		$13.9M Buy
+621,632
New +$13.1M 0.19% 52

Other funds holding DOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

John Paulson's DOVA Position: Q1 2018 in Review

John Paulson sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q1 2018, closing a stake of 550,681 shares — an estimated $13.2M sold.

John Paulson first reported a position in DOVA in Q2 2017 and held it in 3 quarters. The position peaked at $13.9M in Q2 2017. 55 funds tracked by Wall St. Rank hold DOVA as of Q1 2018.

  • John Paulson reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • John Paulson sold 550,681 Dova Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $13.2M.
  • John Paulson first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • John Paulson's Dova Pharmaceuticals, Inc. Common Stock position peaked at $13.9M in Q2 2017.
  • 55 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Paulson & Co's 13F filing for Q1 2018, filed 15 May 2018.